BRPI0608205B8 - derivado heterocíclico-1-carboxilato de piridila não-aromático nitrogenado, composição farmacêutica e uso do dito composto para o tratamento de frequência urinária, incontinência urinária, bexiga hiperativa e dor - Google Patents
derivado heterocíclico-1-carboxilato de piridila não-aromático nitrogenado, composição farmacêutica e uso do dito composto para o tratamento de frequência urinária, incontinência urinária, bexiga hiperativa e dorInfo
- Publication number
- BRPI0608205B8 BRPI0608205B8 BRPI0608205A BRPI0608205A BRPI0608205B8 BR PI0608205 B8 BRPI0608205 B8 BR PI0608205B8 BR PI0608205 A BRPI0608205 A BR PI0608205A BR PI0608205 A BRPI0608205 A BR PI0608205A BR PI0608205 B8 BRPI0608205 B8 BR PI0608205B8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- treatment
- pain
- urinary incontinence
- urinary
- Prior art date
Links
- 206010036018 Pollakiuria Diseases 0.000 title abstract 4
- 206010046543 Urinary incontinence Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000002193 Pain Diseases 0.000 title abstract 2
- 206010020853 Hypertonic bladder Diseases 0.000 title 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 title 1
- 208000020629 overactive bladder Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000022934 urinary frequency Diseases 0.000 title 1
- 230000036318 urination frequency Effects 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 101150042613 FA2H gene Proteins 0.000 abstract 2
- 101150008770 FAAH gene Proteins 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 abstract 1
- 230000003574 anti-allodynic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
derivado heterocíclico-1-carboxilato de piridila não-aromático nitrogenado problemas: fornecer um composto que possa ser usado para o tratamento de uma doença associada à ácido graxo amida hidrolase (faah), particularmente polaquiúria/incontinência urinária, bexiga super-reativa e/ou dor. meios de solucionar os problemas: descobriu-se que um novo derivado éster heterociclico-1-carboxilato de piridila não- aromático nitrogenado e sal farmaceuticamente aceitável do mesmo têm potente atividade inibidora de faah. o derivado é superior no aumento da capacidade efetiva da bexiga e na melhora da polaquiúria e tem um efeito anti-alodinico. com isso, esse composto pode ser usado para o tratamento de polaquiúria/incontinência urinária, bexiga super-reativa e/ou dor.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005040197 | 2005-02-17 | ||
JP2005303065 | 2005-10-18 | ||
PCT/JP2006/302698 WO2006088075A1 (ja) | 2005-02-17 | 2006-02-16 | ピリジル 非芳香族含窒素ヘテロ環-1-カルボン酸エステル誘導体 |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0608205A2 BRPI0608205A2 (pt) | 2009-12-01 |
BRPI0608205B1 BRPI0608205B1 (pt) | 2019-02-05 |
BRPI0608205B8 true BRPI0608205B8 (pt) | 2021-05-25 |
Family
ID=36916476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0608205A BRPI0608205B8 (pt) | 2005-02-17 | 2006-02-16 | derivado heterocíclico-1-carboxilato de piridila não-aromático nitrogenado, composição farmacêutica e uso do dito composto para o tratamento de frequência urinária, incontinência urinária, bexiga hiperativa e dor |
Country Status (20)
Country | Link |
---|---|
US (3) | US7919495B2 (pt) |
EP (2) | EP2607362B1 (pt) |
JP (1) | JP4702361B2 (pt) |
KR (3) | KR101065979B1 (pt) |
CN (1) | CN101160287B (pt) |
AU (3) | AU2006215080B2 (pt) |
BR (1) | BRPI0608205B8 (pt) |
CA (1) | CA2598294C (pt) |
CY (2) | CY1114709T1 (pt) |
DK (2) | DK1849773T3 (pt) |
ES (2) | ES2528674T3 (pt) |
IL (1) | IL184998A (pt) |
MX (1) | MX2007010076A (pt) |
NO (1) | NO20074697L (pt) |
PL (2) | PL2607362T3 (pt) |
PT (2) | PT1849773E (pt) |
RU (3) | RU2408580C2 (pt) |
SI (2) | SI2607362T1 (pt) |
TW (3) | TWI385152B (pt) |
WO (1) | WO2006088075A1 (pt) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200633990A (en) | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
WO2007005510A1 (en) | 2005-06-30 | 2007-01-11 | Janssen Pharmaceutica N.V. | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase |
KR20080025190A (ko) * | 2005-06-30 | 2008-03-19 | 프로시디온 리미티드 | G-단백질 결합된 수용체 효능제 |
WO2007003962A2 (en) * | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
US20090036429A1 (en) * | 2006-02-17 | 2009-02-05 | Ohler Norman E | Hydroxypiperidine Derivatives and Uses Thereof |
US20110172230A1 (en) * | 2006-08-23 | 2011-07-14 | Takahiro Ishii | Urea compound or salt thereof |
DE602007011793D1 (de) | 2006-10-18 | 2011-02-17 | Pfizer Prod Inc | Biaryl-ether-harnstoffverbindungen |
CA2687931C (en) * | 2007-05-31 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
TW201446748A (zh) | 2007-08-22 | 2014-12-16 | Astrazeneca Ab | 環丙基醯胺衍生物 |
BRPI0911118A2 (pt) * | 2008-04-07 | 2015-10-06 | Irm Llc | composto e compisições como moduladores de atividade de gpr119 |
WO2009143404A1 (en) * | 2008-05-23 | 2009-11-26 | Wyeth | Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression |
TWI434842B (zh) | 2008-07-14 | 2014-04-21 | Astellas Pharma Inc | Azole compounds |
US20110212973A1 (en) | 2008-11-06 | 2011-09-01 | Takahiro Ishii | Carbamate compound or salt thereof |
EP2379525B1 (en) | 2008-12-19 | 2015-07-29 | Boehringer Ingelheim International GmbH | Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd |
TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
ES2524829T3 (es) | 2009-12-17 | 2014-12-12 | Boehringer Ingelheim International Gmbh | Nuevos antagonistas del receptor CCR2 y usos de los mismos |
US20130150346A1 (en) | 2010-01-08 | 2013-06-13 | Quest Ventures Ltd. | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome |
KR20120124469A (ko) | 2010-02-05 | 2012-11-13 | 메르크 파텐트 게엠베하 | 헤트아릴-[1,8]나프티리딘 유도체 |
BR112012020629A2 (pt) | 2010-02-18 | 2018-06-19 | Astrazeneca Ab | forma cristalina, e, método para a terapia de um distúrbio |
WO2011123719A2 (en) | 2010-03-31 | 2011-10-06 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating abdominal, visceral and pelvic pain |
JP2013147430A (ja) * | 2010-04-28 | 2013-08-01 | Astellas Pharma Inc | 夜間頻尿の予防又は治療剤 |
TW201206440A (en) * | 2010-04-28 | 2012-02-16 | Astellas Pharma Inc | Prophylactic or therapeutic agent for diseases associated with pains in urinary organs |
WO2011141477A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
JP2013526507A (ja) | 2010-05-12 | 2013-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ccr2受容体アンタゴニスト、その製造方法及び薬物としてのその使用 |
EP2571870B1 (en) | 2010-05-17 | 2015-01-21 | Boehringer Ingelheim International GmbH | Ccr2 antagonists and uses thereof |
US9018212B2 (en) | 2010-05-25 | 2015-04-28 | Boehringer Ingelheim International Gmbh | Pyridazine carboxamides as CCR2 receptor antagonists |
US8962656B2 (en) | 2010-06-01 | 2015-02-24 | Boehringer Ingelheim International Gmbh | CCR2 antagonists |
EP2731941B1 (en) | 2011-07-15 | 2019-05-08 | Boehringer Ingelheim International GmbH | Novel and selective ccr2 antagonists |
BR112015001546B1 (pt) * | 2012-07-24 | 2021-02-23 | Bial-Portela & Ca, S.A | compostos de ureia e sua utilização como inibidores enzimáticos |
DE102012018115A1 (de) | 2012-09-13 | 2014-03-13 | Matthias Lehr | Aryl-N-(arylalkyl)carbamate als Hemmstoffe der Fatty Acid Amide Hydrolase |
GB201218084D0 (en) * | 2012-10-09 | 2012-11-21 | Univ Aston | Novel compounds and methods for use in medicine |
HUP1300139A2 (en) | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
DE102013016573A1 (de) | 2013-10-04 | 2015-04-09 | Matthias Lehr | 1-Tetrazolylpropan-2-one als Inhibitoren von cytosolischer Phospholipase A2 und Fatty Acid Amide Hydrolase, insbesondere geeignet zur topischen Anwendung |
MA41168A (fr) * | 2014-12-17 | 2017-10-24 | Acraf | Nouveaux composés antibactériens |
AU2016287584B2 (en) | 2015-07-02 | 2020-03-26 | Centrexion Therapeutics Corporation | (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate |
EP4335848A2 (en) * | 2017-03-13 | 2024-03-13 | Lundbeck La Jolla Research Center, Inc. | Dual magl and faah inhibitors |
MY172113A (en) * | 2017-07-05 | 2019-11-14 | Frimline Private Ltd | A pharmaceutical composition for neuropathic pain |
US11053199B2 (en) * | 2018-09-13 | 2021-07-06 | Celgene Corporation | Crystalline (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, compositions and methods of use thereof |
WO2020159576A1 (en) | 2019-01-28 | 2020-08-06 | Mitochondria Emotion, Inc. | Mitofusin activators and methods of use thereof |
WO2024072930A1 (en) * | 2022-09-30 | 2024-04-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200462B (pt) * | 1990-09-27 | 1993-02-21 | Hoechst Roussel Pharma | |
US5744485A (en) * | 1994-03-25 | 1998-04-28 | Vertex Pharmaceuticals Incorporated | Carbamates and ureas as modifiers of multi-drug resistance |
AU699619B2 (en) * | 1995-01-11 | 1998-12-10 | Samjin Pharmaceutical Co., Ltd. | New piperazine derivatives and methods for the preparation thereof and compositions containing the same |
US5870472A (en) * | 1996-11-12 | 1999-02-09 | General Instrument Corporation | Dynamic relocation of the service data channel |
US5780484A (en) * | 1996-11-13 | 1998-07-14 | Vertex Pharmaceuticals Incorporated | Methods for stimulating neurite growth with piperidine compounds |
ZA99607B (en) | 1998-01-27 | 1999-07-27 | Rhone Poulenc Rorer Pharma | Substituted oxoazaheterocyclyl factor xa inhibitors. |
CA2366858A1 (en) * | 1999-04-01 | 2000-10-12 | Margaret Yuhua Chu-Moyer | Sorbitol dehydrogenase inhibitors |
HUP0203375A3 (en) | 1999-07-28 | 2005-03-29 | Aventis Pharm Prod Inc | Substituted oxoazaheterocyclyl compounds |
CA2430298A1 (en) | 2000-11-30 | 2002-06-06 | Banavara Lakshman Mylari | Combination of gaba agonists and sorbitol dehydrogenase inhibitors |
ES2275808T3 (es) | 2001-02-06 | 2007-06-16 | Pfizer Products Inc. | Composiciones farmaceuticas para el tratamiento de trastornos del snc y otros trastornos. |
US7067517B2 (en) | 2001-12-14 | 2006-06-27 | Nero Nordisk A/S | Use of compounds for decreasing activity of hormone-sensitive lipase |
JP2003192659A (ja) | 2001-12-26 | 2003-07-09 | Bayer Ag | フェニル尿素誘導体 |
CA2469967A1 (en) | 2001-12-26 | 2003-07-10 | Bayer Healthcare Ag | Urea derivatives as vr1- antagonists |
EP1472215A4 (en) | 2002-02-08 | 2007-05-09 | Bristol Myers Squibb Co | (OXIME) CARBAMOYL, FATTY ACID AMIDE HYDROLASE INHIBITORS |
FR2843964B1 (fr) | 2002-08-29 | 2004-10-01 | Sanofi Synthelabo | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique |
EA010267B1 (ru) * | 2002-10-07 | 2008-06-30 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Модуляция тревоги через блокаду гидролиза анандамида |
TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
EP1636189A1 (en) | 2003-06-12 | 2006-03-22 | Novo Nordisk A/S | 1-aryl-4-(aryloxycarbonyl)-piperazine derivatives for use as inhibitors of hormone sensitive lipase |
KR20060021881A (ko) | 2003-06-12 | 2006-03-08 | 노보 노르디스크 에이/에스 | 호르몬 민감성 리파제의 억제제로서의 사용을 위한 치환된피페리딘 카르바메이트 |
JP2006527212A (ja) | 2003-06-12 | 2006-11-30 | ノボ ノルディスク アクティーゼルスカブ | ホルモン感受性リパーゼの阻害剤として使用するための、置換ピペラジンカルバメート |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
FR2864080B1 (fr) | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
FR2865205B1 (fr) | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
FR2866888B1 (fr) | 2004-02-26 | 2006-05-05 | Sanofi Synthelabo | Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique |
FR2866884B1 (fr) | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique |
CA2608957C (en) * | 2005-05-19 | 2013-12-10 | Astellas Pharma Inc. | Pyrrolidine derivative or salt thereof |
-
2006
- 2006-02-16 RU RU2009121774/04A patent/RU2408580C2/ru active
- 2006-02-16 KR KR1020097011569A patent/KR101065979B1/ko active IP Right Grant
- 2006-02-16 ES ES13160373.0T patent/ES2528674T3/es active Active
- 2006-02-16 PT PT67138396T patent/PT1849773E/pt unknown
- 2006-02-16 CA CA2598294A patent/CA2598294C/en active Active
- 2006-02-16 CN CN200680004214XA patent/CN101160287B/zh active Active
- 2006-02-16 TW TW098121399A patent/TWI385152B/zh not_active IP Right Cessation
- 2006-02-16 KR KR1020097011570A patent/KR101063585B1/ko active IP Right Grant
- 2006-02-16 US US11/816,508 patent/US7919495B2/en active Active
- 2006-02-16 JP JP2007503689A patent/JP4702361B2/ja active Active
- 2006-02-16 KR KR1020077020924A patent/KR101063663B1/ko active IP Right Grant
- 2006-02-16 EP EP13160373.0A patent/EP2607362B1/en active Active
- 2006-02-16 ES ES06713839T patent/ES2433290T3/es active Active
- 2006-02-16 PL PL13160373T patent/PL2607362T3/pl unknown
- 2006-02-16 RU RU2009121775/04A patent/RU2408581C2/ru active
- 2006-02-16 PT PT13160373T patent/PT2607362E/pt unknown
- 2006-02-16 DK DK06713839.6T patent/DK1849773T3/da active
- 2006-02-16 DK DK13160373.0T patent/DK2607362T3/en active
- 2006-02-16 EP EP06713839.6A patent/EP1849773B1/en active Active
- 2006-02-16 WO PCT/JP2006/302698 patent/WO2006088075A1/ja active Application Filing
- 2006-02-16 SI SI200631896T patent/SI2607362T1/sl unknown
- 2006-02-16 AU AU2006215080A patent/AU2006215080B2/en not_active Ceased
- 2006-02-16 MX MX2007010076A patent/MX2007010076A/es active IP Right Grant
- 2006-02-16 PL PL06713839T patent/PL1849773T3/pl unknown
- 2006-02-16 BR BRPI0608205A patent/BRPI0608205B8/pt active IP Right Grant
- 2006-02-16 RU RU2007134441/04A patent/RU2376289C2/ru active
- 2006-02-16 TW TW098121395A patent/TWI385164B/zh not_active IP Right Cessation
- 2006-02-16 SI SI200631681T patent/SI1849773T1/sl unknown
- 2006-02-16 TW TW095105236A patent/TW200640864A/zh not_active IP Right Cessation
-
2007
- 2007-08-02 IL IL184998A patent/IL184998A/en not_active IP Right Cessation
- 2007-09-14 NO NO20074697A patent/NO20074697L/no not_active Application Discontinuation
-
2009
- 2009-08-19 US US12/543,659 patent/US7915261B2/en active Active
- 2009-08-19 US US12/543,690 patent/US7919494B2/en active Active
-
2010
- 2010-06-04 AU AU2010202348A patent/AU2010202348B2/en not_active Ceased
- 2010-06-04 AU AU2010202347A patent/AU2010202347B2/en not_active Ceased
-
2013
- 2013-12-04 CY CY20131101099T patent/CY1114709T1/el unknown
-
2015
- 2015-02-25 CY CY20151100193T patent/CY1116348T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0608205B8 (pt) | derivado heterocíclico-1-carboxilato de piridila não-aromático nitrogenado, composição farmacêutica e uso do dito composto para o tratamento de frequência urinária, incontinência urinária, bexiga hiperativa e dor | |
Crosson et al. | Inhibition of histone deacetylase protects the retina from ischemic injury | |
TWI776407B (zh) | 激動劑形成之調配物及使用其之方法 | |
BRPI0615690B8 (pt) | compostos heterocíclicos de hidroxamato, seus usos e composição farmacêutica | |
ATE456565T1 (de) | Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren | |
Colla et al. | Serotonergic and noradrenergic systems are implicated in the antidepressant-like effect of ursolic acid in mice | |
BR0209957A (pt) | Composto, processo para a preparação de um composto, composição farmacêutica que compreende um composto, utilização desse composto e processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade | |
NO20025601D0 (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
AR074471A1 (es) | Compuesto 5(5-(2-(3-aminopropoxi) - 6 - metoxifenil) -1h- pirazol-3- ilamino ) pirazin -2-carbonitrilo , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para inhibir chk1 y para tratar cancer | |
BR112012018500A2 (pt) | alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas | |
BR0315988A (pt) | Derivados de diidropirimido[4,5-d]pirimidinona substituìda por amino, sua produção e uso como agentes farmacêuticos | |
BR112014006763A2 (pt) | n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1 | |
TW200635912A (en) | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase | |
MXPA05004778A (es) | Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades mieloproliferativas. | |
WO2007061862A3 (en) | 2-keto-oxazoles as modulators of fatty acid amide hydrolase | |
AR075204A1 (es) | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 | |
NO20055216L (no) | Nye hydroksamater som terapeutiske midler | |
EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
DOP2005000039A (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
Kosuge | Neuroprotective mechanisms of S-allyl-L-cysteine in neurological disease | |
BRPI0411936A (pt) | composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade | |
IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same | |
BRPI0409498A (pt) | uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto | |
BR112015020963A2 (pt) | derivado de 2-acilaminotiazola ou sal do mesmo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/02/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/02/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/02/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |